Latest research on Zytiga

Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.

Latest findings

Three standard of care compounds widely used against PrCa were added as controls; namely, the androgen receptor antagonist enzalutamide (MDV3100), the C17α-hydroxylase/C17,20-lyase inhibitor abiraterone (Zytiga), and the classic mitotic inhibitor Paclitaxel. [source, 2015]
The two approved medications, enzalutamide (MDV, XTANDI) and abiraterone acetate (Zytiga), work as an AR signaling inhibitor and a CYP17A1 steroidogenesis inhibitor, respectively. [source, 2015]
Abiraterone acetate (Zytiga) is an irreversible inhibitor of CYP17A1 that is structurally similar to pregnenolone. [source, 2015]
CYP17A1 inhibitors, such as abiraterone acetate (Zytiga), are sought as a potential effective therapy for castrate resistance prostate cancer [117, 119]. [source, 2015]
Recently sipuleucel-T [4], cabazitaxel [5], abiraterone (Zytiga) [6], and MDV3100 [7] have shown more prolonged overall survival benefit and have been approved by the FDA for treatment of the disease. [source, 2015]
Recent studies have shown that abiraterone acetate (Zytiga), an inhibitor of the cytochrome P450 enzyme CYP17, impedes androgen synthesis and thus lowers the level of circulating ligand, improving overall survival in well-powered, randomized phase III studies [source, 2015]
Abiraterone (Zytiga, Janssen, CA, USA) was approved by the U.S. [source, 2015]
Nowadays, oral abiraterone acetate (Zytiga, Janssen Biotech Inc., Horsham, PA, USA) is used in combination with Prednisone or Prednisolone in Europe and the United States for metastatic CRPC previously treated with docetaxel-containing chemotherapy [38]. [source, 2014]
Based on this knowledge, abiraterone acetate (Zytiga) has shown a survival benefit for patients with metastatic castrate resistant prostate cancer (CRPC). [source, 2014]
Recent advances of FDA approved therapies including Enzalutamide (MDV3100), Zytiga (Abiraterone Acetate) and Radium-223 have displayed potential in the clinic. [source, 2014]